Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review

Overview

Journal Adv Ther

Date 2016 Jun 6

PMID 27262452

Citations 8

Authors

Filippo Ansaldi

Cecilia Trucchi

Cristiano Alicino

Chiara Paganino

Andrea Orsi

Giancarlo Icardi

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Herpes zoster (HZ) is a common, painful and debilitating disease caused by the reactivation of latent varicella-zoster virus in ganglia. This clinical event occurs more frequently in the elderly and those who are immunocompromised. The most common complication of HZ is post-herpetic neuralgia (PHN) which is responsible for the highest HZ-related burden of illness and is challenging to treat. Due to the important clinical and economic impact of HZ and PHN, and the suboptimal treatments that are currently available, HZ vaccination is an important approach to reduce the burden of illness. Currently, one-dose, live-attenuated vaccine is licensed in the United States and Europe to prevent HZ and it is included in some national immunization programs. The clinical efficacy, safety and tolerability of the vaccine has been demonstrated in two large phase III clinical trials, involving more than 38,000 and 22,000 individuals aged ≥60 and 50-59 years, respectively. This comprehensive review summarizes the extensive "real-world" effectiveness and safety data from both immunocompetent and immunocompromised individuals. These data confirm those from the clinical trials, supporting the use of HZ vaccine in clinical practice and provide evidence that the current recommendations for immunocompromised individuals should be revised.

Funding: Funding for the editorial assistance, article processing charges, and open access fee for this publication was provided by Sanofi Pasteur MSD.

Citing Articles

Varicella-Zoster Virus Prevalence among Pregnant Women: A European Epidemiological Review.

Bertelli A, Carta V, Mangeri L, Caruso A, De Francesco M Life (Basel). 2023; 13(2).

PMID: 36836948 PMC: 9966538. DOI: 10.3390/life13020593.

Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.

Murdaca G, Noberasco G, Olobardi D, Lunardi C, Maule M, Delfino L Vaccines (Basel). 2021; 9(12).

PMID: 34960174 PMC: 8708328. DOI: 10.3390/vaccines9121426.

Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study.

Yang Q, Chang A, Tong X, Merritt R Stroke. 2021; 52(5):1712-1721.

PMID: 33874749 PMC: 9026696. DOI: 10.1161/STROKEAHA.120.032788.

Nonthermal plasma as part of a novel strategy for vaccination.

Mohamed H, Esposito R, Kutzler M, Wigdahl B, Krebs F, Miller V Plasma Process Polym. 2020; 17(10):2000051.

PMID: 32837491 PMC: 7404442. DOI: 10.1002/ppap.202000051.

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.

Boeckh M, Arvin A, Mullane K, Camacho L, Winston D, Morrison V Open Forum Infect Dis. 2020; 7(7):ofaa172.

PMID: 32665955 PMC: 7336559. DOI: 10.1093/ofid/ofaa172.

References

Cheetham T, Marcy S, Tseng H, Sy L, Liu I, Bixler F . Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015; 90(7):865-73. DOI: 10.1016/j.mayocp.2015.04.021. View

Maggi S, Gabutti G, Franco E, Bonanni P, Conversano M, Ferro A . Preventing and managing herpes zoster: key actions to foster healthy aging. Aging Clin Exp Res. 2015; 27(1):5-11. DOI: 10.1007/s40520-015-0314-7. View

Kawai K, Gebremeskel B, Acosta C . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4(6):e004833. PMC: 4067812. DOI: 10.1136/bmjopen-2014-004833. View

Mori I, Nishiyama Y . Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another?. Rev Med Virol. 2005; 15(6):393-406. DOI: 10.1002/rmv.478. View

Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H . High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis. 1990; 49(8):630-3. PMC: 1004180. DOI: 10.1136/ard.49.8.630. View

Oxman M, Schmader K . Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014; 59(7):920-2. DOI: 10.1093/cid/ciu501. View

Tseng H, Lewin B, Hales C, Sy L, Harpaz R, Bialek S . Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. J Infect Dis. 2015; 212(8):1222-31. PMC: 4902260. DOI: 10.1093/infdis/jiv244. View

Gourishankar S, McDermid J, Jhangri G, Preiksaitis J . Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2003; 4(1):108-15. DOI: 10.1046/j.1600-6143.2003.00287.x. View

Marin M, Yawn B, Hales C, Wollan P, Bialek S, Zhang J . Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015; 11(5):1157-64. PMC: 4514415. DOI: 10.1080/21645515.2015.1016681. View

10.

Sartori A . A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004; 8(5):259-70. DOI: 10.1016/j.ijid.2003.09.006. View

11.

Berman J, Wang M, Berry W, Neuberg D, Guinan E . Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2005; 37(1):73-80. DOI: 10.1038/sj.bmt.1705191. View

12.

Akkara Veetil B, Myasoedova E, Matteson E, Gabriel S, Green A, Crowson C . Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013; 65(6):854-61. PMC: 3674119. DOI: 10.1002/acr.21928. View

13.

Schmader K, Levin M, Gnann Jr J, McNeil S, Vesikari T, Betts R . Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54(7):922-8. PMC: 4542655. DOI: 10.1093/cid/cir970. View

14.

Sampathkumar P, Drage L, Martin D . Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84(3):274-80. PMC: 2664599. DOI: 10.4065/84.3.274. View

15.

Hales C, Harpaz R, Ortega-Sanchez I, Bialek S . Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014; 63(33):729-31. PMC: 5779434. View

16.

Zhang J, Xie F, Delzell E, Chen L, Winthrop K, Lewis J . Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012; 308(1):43-9. PMC: 3683869. DOI: 10.1001/jama.2012.7304. View

17.

Wolfe F, Michaud K, Chakravarty E . Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006; 45(11):1370-5. DOI: 10.1093/rheumatology/kel328. View

18.

Zhang J, Delzell E, Xie F, Baddley J, Spettell C, McMahan R . The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011; 13(5):R174. PMC: 3308109. DOI: 10.1186/ar3497. View

19.

Saag K, Teng G, Patkar N, Anuntiyo J, Finney C, Curtis J . American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-84. DOI: 10.1002/art.23721. View

20.

Watson P . Postherpetic neuralgia. BMJ Clin Evid. 2011; 2010. PMC: 3217735. View